Validation of a competitive ELISA assay for the quantification of human serum hepcidin

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 75, Issue 8, 2015, Pages 652-658

  Dahlfors, Gunilla ^a   Stål, Per ^a   Hansson, Eva C ^a   Bàràny, Peter ^b   Sisowath, Christin ^a   Onelöv, Liselotte ^a   Nelson, Dick ^c   Eggertsen, Gösta ^a   Marmur, Joel ^d   Beshara, Soheir ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c STOCKHOLM UNIVERSITY   (Sweden)

^d ERSTA HOSPITAL   (Sweden)

Author keywords

cELISA; hepcidin 20; hepcidin 22; hepcidin mRNA; LC MS MS

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; HEPCIDIN; HEPCIDIN 20; HEPCIDIN 22; HEPCIDIN 25; IRON; MESSENGER RNA; TRANSFERRIN; UNCLASSIFIED DRUG; HAMP PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROSS REACTION; END STAGE RENAL DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITIN BLOOD LEVEL; GENE EXPRESSION; HEMODIALYSIS PATIENT; HUMAN; HUMAN TISSUE; IRON DEFICIENCY; LIQUID CHROMATOGRAPHY; LIVER BIOPSY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AGED; BLOOD; BLOOD ANALYSIS; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; GENETICS; LIMIT OF DETECTION; LIVER; METABOLISM; MIDDLE AGED; TANDEM MASS SPECTROMETRY; VALIDATION STUDY; YOUNG ADULT;

ADULT; AGED; BLOOD CHEMICAL ANALYSIS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPCIDINS; HUMANS; KIDNEY FAILURE, CHRONIC; LIMIT OF DETECTION; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; RNA, MESSENGER; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84943199068     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2015.1074273     Document Type: Article

References (27)

1. Kroot JJC, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem 2011;57:1650-69.
2. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037-4.
3. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Ped-ersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6.
4. Tessitore N, Girelli D, Campostrini N, Bedogna V, Pietro Solero G, Castagna A, Melilli E, Mantovani W, De Matteis G, Olivieri O, Poli A, Lupo A. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 2010;25:3996-002.
5. Campostrini N, Castagna A, Zaninotto F, Bedogna V, Tessitore N, Poli A, Martinelli N, Lupo A, Olivieri O, Girelli D. Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS. J Biomed Biotechnol 2010;2010:1-7.
6. Pelusi S, Girelli D, Rametta R, Campostrini N, Alfieri C, Traglia M, Dongiovanni P, Como G, Toniolo D, Cam- aschella C, Messa P, Fargion S, Valenti L. The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. BMC Nephrol 2013;14:1-1.
7. van Dijk BAC, Laarakkers CMM, Klaver SM, Jacobs EMG, van Tits LJH, Janssen MCH, Swinkels DW. Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels . Br J Haematol 2008;142:979-85.
8. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7806-10.
9. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T. Synthetic hepcidin causes rapid dose-dependent hypoferrimia and is concentrated in ferroportin-containing organs. Blood 2005:106:2196-9.
10. Nemeth E, Preza GC, Jung CL, Kaplan J, Waring AJ, Ganz T. The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood 2006;107:328-33.
11. Campostrini N, Traglia M, Martinelli N, Corbella M, Cocca M, Manna D, Castagna A, Masciullo C, Silvestri L, Olivieri O, Toniolo D, Camaschella C, Girelli D. Serum levels of the hepcidin-20 isoform in a large general population: the Val Borbera study. J Proteomics 2012;76:28-35.
12. Laarakkers CM, Wiegerinck ET, Klaver S, Kolodziejczyk M, Gille H, Hohlbaum AM, Tjalsma H, Swinkels DW. PLoS One 2013;8:e75518.
13. Kroot JJC, Laarakkers CMM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, Peters HPE, van Dongen-Lases E, Wetzels JFM, Sweep FCGJ, Tjalsma H, Swinkels DW. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders . Clin Chem 2010;56:1570-9.
14. Butterfield AM, Luan P, Witcher DR, Manetta J, Murphy AT, Wroblewski VJ, Konrad RJ. A dual-monoclonal sandwich ELISA specific for hepcidin-25. Clin Chem 2010;56:1725-32.
15. Kroot JJC, Kemna EHJM, Bansal SS, Busbridge M, Campostrini N, Girelli D, Hider RC, Koliaraki V, Mamalaki A, Olbina G, Tomosugi N, Tselepis C, Ward DG, Ganz T, Hendriks JCM, Swinkels DW. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Hae-matologica 2009;94:1748-52.
16. Hedengran KK, Nelson D, Andersen MR, Stender S, Szecsi PB. Hepcidin during pregnancy, delivery and the early postpartum period in women without iron deficiency -a prospective cohort study. J Matern Fetal Neonatal Med 2015;27:1-3.
17. Available from: http://pga.mgh.harvard.edu/primerbank/
18. Sakuraoka Y. Analysis of hepcidin expression: In situ hybridization and quantitative polymerase chain reaction from paraffin sections. World J Gastroenterol 2012;18: 3727-5.
19. Pramfalk C, Parini P, Gustafsson U, Sahlin S, Eriksson M. Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism. J Intern Med 2010;269:333-9.
20. Jiang ZY, Jiang CY, Wang L, Wang JC. Increased NPC1L1 and ACAT2 expression in the jejunal mucosa from Chinese gallstone patients. Biochem Biophys Res Commun 2009;379: 49-54.
21. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
22. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, Wetzels JFM, Kiemeney LALM, Sweep FC, Heijer den M, Swinkels DW. Serum hepcidin: reference ranges and biochemical correlates in the general population . Blood 2011;117:e218-25.
23. Camaschella C. Iron and hepcidin: a story of recycling and balance. Hematology Am Soc Hematol Educ Program. 2013;2013:1-8.
24. Kroot JJC, van Herwaarden AE, Tjalsma H, Jansen RTP, Hendriks JCM, Swinkels DW. Second round robin for plasma hepcidin methods: First steps toward harmonization. Am J Hematol 2012;87:977-83.
25. Ganz T. Systemic iron homeostasis. Physiol Rev 2013;93: 1721-41.
26. Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, Kobold U, Mayer G. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 2009;39:883-90.
27. Peters HPE, Laarakkers CMM, Swinkels DW, Wetzels JFM. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant 2010;25:848-53.